Achillion Reports First Quarter 2018 Financial Results and Management Transition

Achillion Reports First Quarter 2018 Financial Results and Management Transition

IONTAS and aTen Therapeutics Announce Collaboration to Discover Therapeutic Oncology Leads | Business Wire

IONTAS and aTen Therapeutics Announce Collaboration to Discover Therapeutic Oncology Leads | Business Wire: IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by aTen Therapeutics.

Injecting Growth

Injecting Growth: By focusing on its strength in manufacturing lyophilized injectables, Gufic Biosciences has made a strong comeback and wants to aggressively push into the EU market next

Medtronic Announces FDA Approval of Infuse(TM) Bone Graft in New Spine Surgery Indications Using PEEK Interbody Implants

Medtronic Announces FDA Approval of Infuse(TM) Bone Graft in New Spine Surgery Indications Using PEEK Interbody Implants

Global Female Contraceptives Market to 2023 - CAGR Expected to Grow at 8.5% During the Forecast Period - ResearchAndMarkets.com | Business Wire

Global Female Contraceptives Market to 2023 - CAGR Expected to Grow at 8.5% During the Forecast Period - ResearchAndMarkets.com | Business Wire: The

recommandation

Bourse de Paris : Le point sur les changements de recommandations à Paris

0   0

02/05/2018 | 07:41

    PARIS, 2 mai (Reuters) - Principaux changements de recommandations et/ou d'objectifs de
cours enregistrés mercredi à Paris.
    
    * SPIE           - Jefferies entame son suivi avec une recommandation à "sous-performer" et
un objectif de cours à 14,30 euros. Le titre perd 2,19% à 18,32 euros.
    
    * UBISOFT           - KeyBanc reprend sa couverture avec un conseil à "surpondérer" et un
objectif de cours à 94 euros. Le titre gagne 3,96% à 82,4 euros.
    
    * AIRBUS GROUP          - Berenberg relève son objectif de cours à 120 euros contre 96
euros. 
    
    * AKKA          - Portzamparc abaisse sa recommandation à "conserver" contre "acheter" et
revoit son objectif de cours à 60,4 euros contre 61,2 euros. Le titre perd 2,93% à 56,3 euros.
    
    * INFOTEL           - Portzamparc relève sa recommandation à "acheter" contre "renforcer" et
relève son objectif de cours à 62,8 euros contre 61,4 euros. L'action avance de 2,8% à 55 euros.
    
    * GUERBET           - Portzamparc relève sa recommandation à "renforcer" contre "conserver".
Le titre prend 2,67% à 53,9 euros.

    * MADVERTISE            - Midcap Partners abaisse son objectif de cours à 1,6 euro contre
1,8 euro avec un conseil à "acheter" inchangé. L'action chute de 16,13% à 1,17 euros.

 (Service Marchés)

BeiGene Appoints Senior Pharmaceutical Executive Dr. Xiaobin Wu as General Manager of China and President of BeiGene, Ltd.

BeiGene Appoints Senior Pharmaceutical Executive Dr. Xiaobin Wu as General Manager of China and President of BeiGene, Ltd.

Targovax announces early signal of efficacy in ONCOS-102 trial in mesothelioma

Targovax announces early signal of efficacy in ONCOS-102 trial in mesothelioma

Notis från Oasmia Pharmaceutical AB

Notis från Oasmia Pharmaceutical AB

Cotiviti Announces First Quarter 2018 Results | Business Wire

Cotiviti Announces First Quarter 2018 Results | Business Wire: Cotiviti Holdings, Inc. (NYSE:COTV) (“Cotiviti”), a leading provider of payment accuracy and analytics-driven solutions primarily focused on the healt

Aeterna Zentaris to Announce First Quarter 2018 Financial and Operating Results on May 7, 2018

Aeterna Zentaris to Announce First Quarter 2018 Financial and Operating Results on May 7, 2018

Harvard Bioscience Subsidiary Multi Channel Systems Launches Beta Cell Screening System for Diabetes Research, Entering New Segment of Electrophysiology Market

Harvard Bioscience Subsidiary Multi Channel Systems Launches Beta Cell Screening System for Diabetes Research, Entering New Segment of Electrophysiology Market: Multi-Electrode Array (MEA) Offers New Route for Type 2 Diabetes Drug Development and Ability to Elucidate Beta Cell Pathophysiology

Sanofi / Regeneron contraint de réduire ses prix suite à la lenteur des ventes | Pharmafile

Sanofi / Regeneron contraint de réduire ses prix suite à la lenteur des ventes | Pharmafile

German High Street Properties A/S – increase due to merger of share classes

German High Street Properties A/S – increase due to merger of share classes: The share capital of German High Street Properties has been increased due to merger of share classes. The admittance to trading and official listing of shares which have been unlisted until now will take effect as per 3 May 2018 in the ISIN below.

MERCI a toutes et tous de suivre mon blog.bonne fête du 1er Mai

Pages vues aujourd'hui

148

Pages vues hier

88

Pages vues le mois dernier

4 027

Historique global des pages vues

241 498

Frontier Label Designs and Creates Premium Label Experience for Visionary Craft Beer Brewers

Frontier Label Designs and Creates Premium Label Experience for Visionary Craft Beer Brewers: From creative concepts to beautiful labels, Frontier Label simplifies the labeling process for beer companies to attract the attention of customers

Analysis of the APAC Cardiac Troponin Diagnostics Market - Forecast to 2021 - ResearchAndMarkets.com | Business Wire

Analysis of the APAC Cardiac Troponin Diagnostics Market - Forecast to 2021 - ResearchAndMarkets.com | Business Wire: The

http://www.marketwired.com/press-release/moleculin-announces-new-data-immuno-stimulating-drug-be-presented-international-conference-nasdaq-mbrx-2246694.htm

http://www.marketwired.com/press-release/moleculin-announces-new-data-immuno-stimulating-drug-be-presented-international-conference-nasdaq-mbrx-2246694.htm

http://www.marketwired.com/press-release/advanzeon-solutions-inc-expands-management-team-and-presence-in-california-otcbb-chcr-2246708.htm

http://www.marketwired.com/press-release/advanzeon-solutions-inc-expands-management-team-and-presence-in-california-otcbb-chcr-2246708.htm

http://www.marketwired.com/press-release/fda-authorizes-ctd-proceed-with-extension-protocol-us-phase-i-trappsolr-cyclo-trial-otcqb-ctdh-2246705.htm

http://www.marketwired.com/press-release/fda-authorizes-ctd-proceed-with-extension-protocol-us-phase-i-trappsolr-cyclo-trial-otcqb-ctdh-2246705.htm